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Abstract
Introduction National competent authorities (NCAs) use
Direct Healthcare Professional Communications (DHPCs)
to communicate new drug safety issues to healthcare pro-
fessionals (HCPs). More knowledge is needed about the
effectiveness of DHPCs and the extent to which they raise
awareness of new safety issues among HCPs.
Objective The objective was to assess and compare gen-
eral practitioners’ (GPs’), cardiologists’, and pharmacists’
familiarity with DHPCs as communication tools, their
awareness of specific drug safety issues, and the sources
through which they had become aware of the specific
issues.
Methods GPs, cardiologists, and pharmacists from nine
European countries (Croatia, Denmark, Ireland, Italy, the
Netherlands, Norway, Spain, Sweden, and the UK) com-
pleted a web-based survey. The survey was conducted in
the context of the Strengthening Collaboration for Oper-
ating Pharmacovigilance in Europe (SCOPE) Joint Action.
Respondents were asked about their familiarity with
DHPCs in general and their awareness of safety issues that
had recently been communicated and involved the fol-
lowing drugs: combined hormonal contraceptives,
diclofenac, valproate, and ivabradine. Those HCPs who
were aware of the specific safety issues were subsequently
asked to indicate the source through which they had
become aware of them. Differences between professions in
familiarity with DHPCs and awareness were tested using a
Pearson v2 test per country and post hoc Pearson v2 tests in
the case of statistically significant differences.
Results Of the 3288 included respondents, 54% were GPs,
40% were pharmacists, and 7% were cardiologists. The
number of respondents ranged from 67 in Denmark to 916
in Spain. Most respondents (92%) were familiar with
DHPCs, with one significant difference between the pro-
fessions: pharmacists were more familiar than GPs in Italy
(99 vs 90%, P = 0.004). GPs’ awareness ranged from 96%
for the diclofenac issue to 70% for the ivabradine issue. A
similar pattern was shown for pharmacists (91% aware of
the diclofenac issue to 66% of the ivabradine issue). Car-
diologists’ awareness ranged from 91% for the ivabradine
issue to 34% for the valproate issue. Overall, DHPCs were
a common source through which GPs (range: 45% of those
aware of the contraceptives issue to 60% of those aware of
the valproate issue), cardiologists (range: 33% for the
contraceptives issue to 61% for the valproate issue), and
pharmacists (range: 41% for the contraceptives issue to
51% for the ivabradine issue) had become aware of the
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specific safety issues, followed by information on websites
or in newsletters.
Conclusions GPs, cardiologists, and pharmacists were to a
similar extent (highly) familiar with DHPCs, but they
differed in awareness levels of specific safety issues. Car-
diologists were less aware of safety issues associated with
non-cardiology drugs even if these had cardiovascular
safety concerns. This implies that additional strategies may
be needed to reach specialists when communicating safety
issues regarding drugs outside their therapeutic area but
with risks related to their field of specialisation. DHPCs
were an important source for the different professions to
become aware of specific safety issues, but other sources
were also often used. NCAs should consider the use of a
range of sources when communicating important safety
issues to HCPs.
Key Points
Familiarity with Direct Healthcare Professional
Communications (DHPCs) was high among general
practitioners (GPs), cardiologists, and pharmacists
across Europe.
Cardiologists were more aware than GPs of the
safety issue for a drug within their field of expertise
(ivabradine) and less aware than GPs and
pharmacists of safety issues of other drugs
(contraceptives, diclofenac, and valproate), despite
some of these relating to cardiovascular risks.
DHPCs were an important source for GPs,
cardiologists, and pharmacists to become aware of
specific safety issues, but other sources, such as
websites or newsletters and medical journals, were
also relevant.
1 Introduction
There have been some high-profile drug safety issues in
recent years where re-evaluation of the risks associated
with drugs such as rosiglitazone and sibutramine led to
their removal from the market by European regulators as
the benefit–risk balance was judged to be negative [1, 2].
More often, however, important new safety issues emerge
where the overall benefit–risk balance of the drug remains
positive provided healthcare professionals (HCPs) take into
account certain warnings and precautions and the drug
remains on the market. In these cases, national competent
authorities (NCAs) inform HCPs about these risks and the
actions that they should take to minimise or manage them.
Research, however, has shown that the safety advice in
communications from regulators is not always followed
[3–5]. Before HCPs can act on a safety issue, they first
need to become aware of it. A study published in 2012
among a sample of Dutch HCPs showed mixed awareness
of drug safety issues, ranging from 56% of HCPs being
aware of new safety issues with etoricoxib up to 88% for
clopidogrel [6]. Moreover, it was shown that awareness
varied among professions, where pharmacists were gener-
ally more aware of safety issues than general practitioners
(GPs) [6].
Direct Healthcare Professional Communications
(DHPCs) are an important tool that NCAs use to commu-
nicate new drug safety information to HCPs [7]. DHPCs
are letters predominantly distributed by pharmaceutical
companies following content approval by the NCAs. Some
research suggests that about one-fifth of HCPs are not
familiar with these communications. Again, differences
between professions were seen, with GPs being more
familiar with these communications than pharmacists [6].
Besides DHPCs, NCAs can use additional tools to raise
awareness of safety issues, such as the NCA’s own com-
munications (e.g. newsletters) [7]. Currently, it is not
known how HCPs become aware of safety issues (i.e. via
DHPCs or other sources) and whether this differs between
professions. A previous study showed that NCAs from
European countries generally use similar methods for
safety communication, but that GPs’ awareness of safety
communication tools differ across countries [8].
The aim of this study was to expand the current knowledge
about differences between professions in familiarity with
DHPCs and awareness of safety issues in various European
countries. More specifically, our aims were to compare GPs,
cardiologists, and pharmacists regarding their familiarity with
DHPCs, their awareness of specific recent drug safety issues,
and the sources through which they have become aware of
these issues. This knowledge is important for NCAs in the
evaluation of their current safety communication strategies
and to facilitate improvement in the future. Knowing how
different professions perceive current drug safety communi-
cation tools and the sources they used most in informing
themselves of important updates can help NCAs to optimise
their safety communication strategies.
2 Methods
2.1 Study Design and Data Collection
Cross-sectional data from a web-based survey about HCPs’
views and experiences regarding drug safety information
S. T. de Vries et al.
were used for this study. The data were collected in the
year 2015 in the context of the Strengthening Collaboration
for Operating Pharmacovigilance in Europe (SCOPE) Joint
Action Work Package 6 (http://www.scopejointaction.eu/).
The active partners in this work package developed the
survey in the English language (see Electronic Supple-
mentary Material 1). This survey was translated by an
official translation agency in the following languages:
Croatian, Danish, Dutch, Italian, Norwegian, Spanish, and
Swedish. Thereafter, the surveys were back-translated and
pilot tested to check whether the translations had the same
meaning as the English version and whether the survey was
understandable for people not involved in the project.
Unipark software (http://www.unipark.com/en/) was used
to create the web-based format of the survey. Ethical
approval was not considered necessary because of the
nature of the study, in which HCPs were asked to complete
a survey about safety communication strategies.
2.2 Participants
The survey was distributed among HCPs in nine European
countries that were active partners in Work Package 6 of
the Joint Action; i.e. Croatia, Denmark, Ireland, Italy, the
Netherlands, Norway, Spain, Sweden, and the UK. HCPs
were recruited via a link to the survey on websites, in
newsletters, and/or in an email sent by the NCA, a pro-
fessional body, or a commercial organisation to all their
subscribers or members. HCPs that were actively targeted
and included in this study were GPs, cardiologists, and
pharmacists. In Spain and Sweden, only GPs and cardiol-
ogists were actively targeted.
2.3 Outcome Assessment
To assess HCPs’ familiarity with DHPCs the survey con-
tained a short introduction about DHPCs with two exam-
ples pictured, after which respondents were asked the
following closed-ended question: ‘‘Are you familiar with
this type of safety communication?’’ Respondents
answering ‘‘Yes’’ were considered familiar, whereas
respondents answering ‘‘No, I have heard of DHPCs, but I
have never seen one’’ or ‘‘No, I have never heard of
DHPCs’’ were considered unfamiliar with DHPCs.
HCPs’ awareness of specific safety issues was assessed
using the following question: ‘‘Are you aware of updates to
the safety profiles of the following medicines?’’ The pre-
sented drug safety issues were updates on the risk of
thrombosis with combined hormonal contraceptives (con-
traceptives), cardiovascular harms with diclofenac, terato-
genicity with valproate, and cardiovascular events with
ivabradine (Table 1). These safety issues were chosen as
they had been the subject of NCA safety communications
in the period just prior to the survey being conducted
[following review within safety referral procedures by the
Pharmacovigilance Risk Assessment Committee (PRAC)],
and to have a representative sample of drugs used in pri-
mary care (contraceptives and diclofenac) along with spe-
cialised care (valproate and ivabradine). The safety issue
for ivabradine was not included in the Norwegian survey
because this drug is not on the market in Norway.
Finally, when respondents indicated that they were
aware of a certain safety issue, they were asked how they
had heard about it. The source options provided were as
follows: via a DHPC, a website or newsletter, educational
materials, a professional body, a colleague, a medical
journal, lay media (newspaper/television), or other source.
The Norwegian survey included an additional answer
option, i.e. through the national medicines agency. It was
possible to provide multiple answers on how HCPs became
aware of the safety issues.
2.4 Analyses
Descriptive information about the included population is
presented as frequencies with percentages for the total
population and per profession.
HCPs’ familiarity with DHPCs and awareness of each of
the four specific safety issues are presented as percentages
per profession within each country. Only HCPs who were
familiar with DHPCs were included in the assessment of
awareness of the safety issues. Differences in familiarity
with DHPCs and awareness between professions were
tested using a Pearson v2 test per country. In the case of a
statistically significant result (P value of\0.05), Pearson
v2 tests were used to assess which professions differed
from each other. A Bonferroni adjustment to correct for
multiple testing (N = 3) was used for these post hoc tests,
implying that a P value of\0.016 was considered statis-
tically significant.
Data from the sources through which the HCPs heard of
the safety issues were analysed descriptively. The results of
these analyses are presented per profession using percentages
per safety issue and per country for those HCPs who were
aware of the safety issue. The additional answer option in the
Norwegian survey was classified as ‘‘other’’ sources.
All analyses were conducted using Stata version 13 (Stata
Corp., College Station, TX, USA), and Microsoft Excel 2010
was used for the graphical presentation of the results.
3 Results
In total, 3625 HCPs completed the survey, of whom 337
had a profession different than the target population of
GPs, cardiologists, and pharmacists. Of the remaining 3288
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Risk of VTE. Confirmation
that the absolute risk of VTE
with all CHCs is small and
ranges from 5 to 12 cases of
VTE per 10,000 women per
year, but that differences
exist depending on the type
of progestogen they contain






the lowest risk as per the
available evidence
Risk of cardiovascular events.
The same cardiovascular
precautions now apply for
diclofenac as for selective
COX-2 inhibitors, i.e.
‘coxibs’
Risk of teratogenicity. Further
characterisation of the
teratogenic effects: children
exposed in utero are at a
high risk of serious
developmental disorders (in
up to 30–40% of cases) and/
or congenital malformations
(in approximately 10% of
cases)
Risk of cardiovascular events.
A small but significant
increase of the combined
risk of cardiovascular death,
myocardial infarction, and
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Valproate should not be used
in female children/
adolescents of childbearing
potential or pregnant women
unless other treatments are
ineffective or not tolerated.
It must be started and
supervised by a doctor
experienced in managing
epilepsy or bipolar disorder.
All female patients must be
informed of and fully
understand the risks of use
during pregnancy
Ivabradine is indicated only
for symptomatic treatment
of chronic stable angina
pectoris because ivabradine
has no benefits on
cardiovascular outcomes
(e.g. myocardial infarction
or cardiovascular death) in
patients with symptomatic
angina. Serial heart rate
measurements are required
prior to initiation of therapy
or prior to dose titration.
Concomitant use with
verapamil or diltiazem is
contraindicated. Treatment
should only be initiated in
patients with a resting heart
rate of at least 70 bpm
Year of DHPC 2014 2013 2014 2014
Distribution of DHPC per country
Format
Croatia Hardcopy, point-of-care alerts
for HCPs at primary level,
NCA website and newsletter
Hardcopy, point-of-care alerts
for HCPs at primary level,
NCA website and newsletter
Hardcopy, point-of-care alerts
for HCPs at primary level,
NCA website and newsletter
Hardcopy, point-of-care alerts
for HCPs at primary level,
NCA website and newsletter
Denmark Electronic and NCA website Hardcopy and NCA website Hardcopy and NCA website Hardcopy and NCA website
Ireland Hardcopy letter (also
published on NCA website
and article included in
electronic NCA newsletter)
Hardcopy letter (also
published on NCA website
and article included in
electronic NCA newsletter)
Hardcopy letter (also
published on NCA website
and article included in
electronic NCA newsletter)
Hardcopy letter (also
published on NCA website
and article included in
electronic NCA newsletter)
Italy Hardcopy and NCA website Hardcopy and NCA website Hardcopy and NCA website Hardcopy and NCA website
Netherlands Hardcopy, NCA website and
NCA newsletter
Hardcopy, NCA website and
NCA newsletter
Hardcopy, NCA website and
NCA newsletter
Hardcopy, NCA website and
NCA newsletter












Spain Electronic and NCA website Electronic and NCA website Electronic and NCA website Electronic and NCA website
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respondents, 54% were GPs, 40% were pharmacists, and
7% were cardiologists (Fig. 1). The number of respondents
ranged from 67 in Denmark to 916 in Spain. Most of the
GPs, cardiologists, and pharmacists were from, respec-
tively, Spain (N = 847), Italy (N = 63), and Norway
(N = 381) (Fig. 2). More than half of the respondents per
country were female, except for Italy (42% female) and the
Netherlands (31% female) (see Electronic Supplementary
Material 2).
3.1 Familiarity with DHPCs
Most respondents (92%) were familiar with DHPCs, and in
general there were only small differences between GPs,
cardiologists, and pharmacists in terms of their familiarity
(Fig. 3). Only in Italy a significant difference between the
professions was shown (P = 0.016). More pharmacists
were familiar with DHPCs than GPs (99 vs 90%,
P = 0.004). Familiarity was highest in Ireland, Italy,
Spain, and the UK, where more than 90% of the GPs,
cardiologists, and pharmacists were familiar with DHPCs.
Familiarity was lowest for some professions in Sweden (i.e.
GPs), Croatia (i.e. cardiologists), and Norway (i.e.
pharmacists).
3.2 Awareness of the Four Specific Safety Issues
Overall, GPs were most aware of the safety issue con-
cerning diclofenac (96%), followed by contraceptives
(88%), valproate (76%), and ivabradine (70%). The same
pattern was shown for the pharmacists, with highest
awareness of diclofenac (91%), followed by contraceptives
(90%), valproate (80%), and ivabradine (66%). For the
cardiologists, the pattern was different, with highest
awareness of the ivabradine safety issue (91%), followed
by diclofenac (79%), contraceptives (61%), and valproate
(34%).
Cardiologists were significantly less aware of the con-
traceptives safety issue than GPs and/or pharmacists in six
countries (i.e. Denmark, Italy, the Netherlands, Norway,
Spain, and the UK) (Fig. 4a). In three countries (i.e. Spain,
Italy, and Norway), they were also less aware of the
diclofenac issue (Fig. 4b). For the valproate issue, cardi-
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Croatia MAH MAH MAH MAH
Denmark NCA MAH MAH MAH
Ireland MAH MAH MAH MAH
Italy MAH MAH MAH MAH
Netherlands MAH MAH MAH MAH
Norway MAH MAH MAH N/A
Spain Learned societies of targeted
HCPs
Learned societies of targeted
HCPs
Learned societies of targeted
HCPs
Learned societies of targeted
HCPs
Sweden MAH MAH MAH MAH
UK NCA MAH NCA MAH
CHCs combined hormonal contraceptives, COX cyclo-oxygenase, DHPC Direct Healthcare Professional Communication, GP general practitioner,
HCP healthcare professional, MAH marketing authorisation holder, N/A not applicable, NCA national competent authority, PhV pharmacovigilance,
VTE venous thromboembolism
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five countries (i.e. Italy, the Netherlands, Norway, Spain,
and the UK) (Fig. 4c). In Sweden, GP awareness of the
valproate issue was low and cardiologists were more aware
of this safety issue; respectively, 38 vs 69%, P = 0.033.
For the ivabradine issue, cardiologists were more aware
than GPs in four countries (i.e. Croatia, the Netherlands,
Sweden, and the UK) (Fig. 4d).
Some differences between GPs and pharmacists were
also observed (Fig. 4). Pharmacists were more aware of the
contraceptives’ safety issue than GPs (Croatia 96 vs 83%,
P = 0.003; Italy 97 vs 88%, P = 0.009). They were also
more aware of the ivabradine issue (Netherlands 56 vs
21%, P\0.001). An inconsistent pattern across the coun-
tries was shown for the diclofenac and valproate issue. For
the diclofenac issue, pharmacists were more aware than
HCPs who completed the 
survey: N = 3,625  
Target populaon: N = 3,288
GPs: N = 1,766 (54%) 
Cardiologists: N = 222 (7%) 
Pharmacists: N = 1,300 (40%)  
Other profession: N = 337  
Completers 
Profession 
Yes: N = 3,016
No: N = 272* (8%) 
Familiarity with 
DHPCs 
Response to speciﬁc 
safety issue 
Respondents with a missing 
answer to all of the four safety 
issues: N = 3 
Addionally excluded per safety 
issue due to missing answers:
- Contracepves: N = 12 
- Diclofenac: N = 18 
- Valproate: N = 24
- Ivabradine: N = 432† 
Included in the analyses of aim 1: familiarity with DHPCs 
Included per safety issue: 
- Contracepves: N = 3,001 
- Diclofenac: N = 2,995 
- Valproate: N = 2,989 
- Ivabradine: N = 2,581† 
Included in the analyses of aim 2: Awareness of speciﬁc safety issues 
Not aware of the safety issue:
- Contracepves: N = 390 (13%) 
- Diclofenac: N = 205 (7%) 
- Valproate: N = 752 (25%)
- Ivabradine: N = 771† (30%) 
Included per safety issue: 
- Contracepves: N = 2,611 
- Diclofenac: N = 2,790 
- Valproate: N = 2,237 
- Ivabradine: N = 1,810† 
Included in the analyses of aim 3: Sources through which HCPs became aware 
Awareness of 
speciﬁc safety issues 
Fig. 1 Flowchart of number of healthcare professionals (HCPs)
included per study aim. *272 responding HCPs were excluded: 135
had heard of Direct Healthcare Professional Communications
(DHPCs), but had never seen one; 136 had never heard of DHPCs;
and 1 skipped the question. This safety issue was not included in the
survey in Norway. GPs general practitioners
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GPs in the UK (99 vs 95%, P = 0.009), but less aware in
Ireland (83 vs 93%, P = 0.006). For the valproate issue,
pharmacists were more aware than GPs in Ireland (90 vs
65%, P\0.001), in the UK (86 vs 68%, P\0.001), and in
the Netherlands (69 vs 45%, P = 0.006), but they were less
aware in Norway (66 vs 81%, P = 0.008).
3.3 Sources
Most of the GPs who were aware of a specific safety issue
indicated that they had heard about this through a DHPC
(range: 45% of those aware of the contraceptives issue to
60% of those aware of the valproate issue), followed by a
message on a website or in a newsletter (range: 37% of
those aware of the valproate issue to 39% of those aware of
the other issues) (see Electronic Supplementary Material
3). For many cardiologists, DHPCs were also mentioned as
an important source (range: 33% for the contraceptives
issue to 61% for the valproate issue), but in addition,
medical journals were often mentioned for the contracep-
tives issue (46%), ivabradine issue (42%), and diclofenac
issue (34%). A message on a website or in a newsletter was
the source for 20% (contraceptives issue) to 30% (val-
proate issue) for the cardiologists. The sources most often
mentioned by pharmacists were DHPCs (range: 41% for
the contraceptives issue to 51% of the ivabradine issue) and
information on a website or in a newsletter (range: 42% for
the contraceptives and valproate issues to 46% for the
diclofenac and ivabradine issues).
There was variation across the countries in the sources
through which HCPs had become aware of the safety issues
(see Electronic Supplementary Material 3). For instance,
information provided by professional bodies was more
often the source for HCPs in the Netherlands than for HCPs
in the other countries. Another example is the ‘‘other’’
source through which somewhat more HCPs from Norway
became aware of the issues compared to the number of
HCPs from other countries. This other source contained the
NCA’s own information centre, which was only specifi-
cally evaluated in the Norwegian survey. More HCPs from
Italy became aware through a DHPC than did HCPs from
other countries.
4 Discussion
This study shows that most GPs, cardiologists, and phar-
macists across Europe are familiar with DHPCs. In general,
GPs and pharmacists were more aware of the safety issues
concerning contraceptives and diclofenac than
 General praconers Pharmacists Cardiologists 
Croaa 85 4 104 
Denmark 25 7 35 
Ireland 144 5 281 
Italy 183 63 104 
Netherlands 72 17 64 
Norway 105 40 381 
Spain 847 56 13 
Sweden 108 15 N/A 
































P = 0.004 Fig. 3 Familiarity with Direct
Healthcare Professional
Communications (DHPCs) by
profession per country. 1Despite
not being targeted, a few
pharmacists from Spain
completed the survey. 2In
Sweden, pharmacists were not







































Croaa 0.010 0.427 0.721 0.003 
Denmark 0.000 0.001 0.000 
Ireland 0.714    
Italy 0.000 0.003 0.000 0.009 
Netherlands 0.010 0.002 0.049 0.187 
Norway 0.000 0.000 0.000 0.043 
Spain1 0.000 0.000 0.002 0.768 
Sweden2 0.820    
UK 0.001 0.002 0.000 0.367 






Croaa 0.073    
Denmark 0.162    
Ireland 0.020 0.256 0.837 0.006 
Italy 0.000 0.000 0.000 0.461 
Netherlands 0.089    
Norway 0.002 0.001 0.001 0.413 
Spain1 0.000 0.000 0.066 0.588 
Sweden2 0.292    
UK 0.021 0.691 0.045 0.009 






Croaa 0.038 0.020 0.061 0.138 
Denmark 0.092    
Ireland 0.296    
Italy 0.078    
Netherlands 0.000 0.000 0.162 0.000 
Norway     
Spain1 0.254    
Sweden2 0.000 
UK 0.024 0.009 0.018 0.267 






Croaa 0.069    
Denmark 0.068    
Ireland 0.000 0.493 0.478 0.000 
Italy 0.000 0.000 0.000 0.053 
Netherlands 0.000 0.008 0.000 0.006 
Norway 0.000 0.000 0.000 0.008 
Spain1 0.000 0.000 0.000 0.134 
Sweden2 0.033 
UK 0.000 0.001 0.000 0.000 
 DiclofenacCombined Hormonal Contracepves
Ivabradine3Valproate
Fig. 4 Awareness of four specific safety issues by profession and
P values for differences between professions within countries. P val-
ues in bold are considered statistically significant. 1Despite not being
targeted, a few pharmacists from Spain completed the survey. 2In
Sweden, pharmacists were not actively targeted and no pharmacists
completed the survey. 3The ivabradine safety issue was not assessed
in Norway. Card cardiologists, GPs general practitioners, Pharm
pharmacists
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cardiologists, whereas cardiologists were more aware of
the ivabradine issue, which is largely expected given its use
in the specialist setting only. We showed some differences
between GPs and pharmacists, but these differed across the
countries. DHPCs were most often mentioned by all three
professions as the source through which HCPs had become
aware of the safety issues, but other sources were also
relevant depending on the safety issue and profession as
well as the country.
A previous study conducted in the Netherlands showed
differences between GPs and hospital pharmacists in their
familiarity with DHPCs [6]. Our study showed a difference
between GPs and pharmacists only in Italy. This previous
study found that 28% of the GPs were not familiar with
DHPCs compared to 14% of the GPs from the Netherlands
in our study. This may imply that familiarity with DHPCs
among GPs in the Netherlands has increased over the years.
In general, there seems to be still room for improvement,
with less than 80% of respondents in some professions
reporting to be familiar with DHPCs (Croatia and Norway).
Of the four presented safety issues, GPs and pharmacists
were least aware of the ivabradine issue. This lower
awareness may be due to the fact that ivabradine is a newer
active substance, likely to be prescribed by specialists, and
authorised for a relatively narrow indication. Not surpris-
ingly, this was the safety issue of which cardiologists were
most aware. On the other hand, cardiologists were less
aware of safety issues of drugs that are primarily prescribed
in general practice (i.e. contraceptives and diclofenac),
which is still of cause for concern since the communica-
tions referred to cardiovascular-related risks. A previous
study had also shown that specialists were less aware than
GPs and community pharmacists of a safety issue for a
drug prescribed and dispensed in primary care [6]. An
important explanation may be that DHPCs about contra-
ceptives and diclofenac were not sent to cardiologists in all
countries (Table 1). This indicates that in the evaluation of
the effectiveness of safety communication strategies,
awareness among the targeted professions should be
assessed rather than awareness among HCPs in general.
Findings, however, were not completely consistent as some
professional groups received a DHPC but were less aware.
Further studies should assess whether cardiologists and
other specialists are also interested in receiving DHPCs
about adverse effects relevant for their specialty, instead of
only receiving DHPCs for drugs used to treat specialty-
related diseases.
In three countries (i.e. Ireland, the Netherlands, and the
UK), pharmacists were more aware of a safety issue about
a drug primarily prescribed by specialists (i.e. valproate)
than GPs. However, in Norway, GPs were more aware of
this issue than pharmacists. There may be various reasons
for this and for other observed differences across countries
in our study. One reason could be differences between
countries in uptake of a certain drug and healthcare systems
(e.g. whether treatment is confined to the specialised set-
ting in clinics/hospitals or initiated/repeated by GPs).
Another reason could be differences across European
countries in NCAs’ communication strategies. Although a
previous study showed that NCAs use similar methods to
communicate about drug safety issues [8], the current study
showed differences across the countries in the sources
through which HCPs had become aware of the specific
safety issues. Moreover, there were differences between
and within countries with respect to the format, the target
population, and the sender of the communication about the
specific safety issues (Table 1). Various factors related to
these strategies, such as trust in the sender of the infor-
mation, may have influenced the uptake of the information
[10]. Future studies should focus more on the explanations
for differences across European countries. In addition,
future studies should focus on whether high awareness
actually translates into improved drug utilisation and health
outcomes; however, study methods other than surveys are
needed for such evaluations [11]. A recent systematic
review showed that in more than half of the reviewed
studies evaluating the impact of regulatory interventions,
administrative claims databases or electronic health records
databases were used [12].
Although there is room for improving HCPs’ familiarity
with DHPCs, this communication tool was the most com-
mon source through which the HCPs became aware of the
safety issues included in our study. Information on a
website or in a newsletter was also reported as an important
source for many HCPs; in some cases these are likely to be
the websites and newsletters of NCAs, which are long
established in some countries [8]. Interestingly, medical
journals were also commonly used by cardiologists aware
of the contraceptive, diclofenac, and ivabradine issues. To
improve HCPs’ awareness of safety issues and ultimately
their actual prescribing/dispensing behaviour, it is therefore
important that the strategies for safety communication
should be tailored to specific professions. There may also
be differences in the use of sources per country. For
instance, in the Netherlands, awareness of the contracep-
tives and diclofenac safety issues were higher than the
awareness of the valproate and ivabradine issues. This may
be related to the role of ‘‘professional bodies’’ that were
indicated in the Netherlands as an important source, and
that thus may amplify safety messages from NCAs.
Interestingly, several HCPs claimed to have heard about
the diclofenac safety issue via educational materials despite
these materials not being disseminated for this drug safety
issue. This finding indicates that HCPs may have confused
the regulatory term ‘‘educational materials’’ with other
educational activities, despite examples of educational
S. T. de Vries et al.
materials being presented within the survey for clarity,
suggesting a broader interpretation of this term than the
regulatory meaning.
A strength of this study is the inclusion of survey
respondents from a wide range of European countries; thus
it was possible to assess the associations per country.
However, the study also has some limitations. One limi-
tation relates to the use of a survey methodology which
could have introduced biases such as recall bias and
answering tendencies [13]. Moreover, survey answering
tendencies such as socially desirable answering may differ
across countries [14, 15], which could have influenced our
results. Another limitation is the low statistical power in
some countries due to the small sample size, particularly
the low number of included cardiologists. Results should
therefore be interpreted cautiously. Due to the low sample
size, we did not assess the sources by profession per
country, and this also limits the generalisability of the
findings. Previously, we compared the GPs included in our
study with the total GP population in the different countries
and we observed a similar pattern in terms of age and sex
distribution [8]. However, representativeness cannot be
guaranteed, particularly in countries with small sample
sizes. In addition, pharmacists were not actively recruited
in Spain and Sweden and other specialists that would have
been relevant to the specific safety issues studied (e.g.
neurologists or epileptologists) were not included.
5 Conclusion
We observed high familiarity with DHPCs across all three
professions; however, there were differences between
professions in awareness of specific safety issues. GPs and
pharmacists were more aware of the safety issues con-
cerning contraceptives and diclofenac than cardiologists,
whereas cardiologists were more aware of the ivabradine
issue. Different strategies may be needed to reach spe-
cialists when communicating safety issues regarding drugs
outside their therapeutic area but with risks related to their
field of specialisation. Aside from DHPCs, other sources
such as websites, newsletters, professional bodies, or
medical journals can be relevant sources for HCPs to
become aware of safety issues. Our findings suggest that
NCAs should explore the use of other information sources
to complement the current tools used to disseminate safety
information.
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